DM
BCRX icon

Deerfield Management’s BioCryst Pharmaceuticals BCRX Stock Holding History

Deerfield Management’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-500,000
Closed -$2.78M – 92
2017
Q2 		$2.78M Buy
+500,000
New +$3.05M 0.15% 78

Other funds holding BCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Deerfield Management's BCRX Position: Q2 2026 in Review

Deerfield Management increased its BioCryst Pharmaceuticals (BCRX) stake by 0.39% in Q2 2026, buying an estimated $528K and bringing the position to 15,096,403 shares worth $151M. The position accounts for 1.57% of the portfolio, ranked #17.

Deerfield Management first reported a position in BCRX in Q3 2013 and has held it in 40 quarters since. 319 funds tracked by Wall St. Rank hold BCRX as of Q2 2026.

  • Deerfield Management held 15,096,403 shares of BioCryst Pharmaceuticals worth $151M as of Q2 2026.
  • Deerfield Management bought 58,403 BioCryst Pharmaceuticals shares in Q2 2026, an estimated $528K.
  • BioCryst Pharmaceuticals made up 1.57% of Deerfield Management's portfolio in Q2 2026, its #17 holding.
  • Deerfield Management first reported a position in BioCryst Pharmaceuticals in Q3 2013 and has held it in 40 quarters since.
  • 319 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2026.

Based on Deerfield Management's 13F filing for Q2 2026, filed 14 Aug 2026.